William B. Mattes Data-verified
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
Senior Scientific Advisor
faculty
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
William B. Mattes' research focuses on understanding the toxicological effects of various substances, particularly in relation to human health and drug development. His work investigates how compounds interact with biological systems at the molecular and cellular levels, aiming to predict and assess potential adverse outcomes. This includes studies on drug-induced toxicity, such as cardiotoxicity and liver mitochondrial dysfunction, utilizing advanced in vitro models and omics technologies.
Mattes has published extensively on the application of metabolomics as a translational tool in precision medicine and has contributed to discussions on the identification and terminology of multicomponent biomarkers. His research also explores the development and validation of novel methods for toxicity screening, including the use of human-based multiple organ MPS (microphysiological systems) and cardiac NAMs (New Approach Methodologies). His collaborations with researchers at the National Center for Toxicological Research, including Li Pang, Katy S Papineau, Lijun Ren, and Laura K. Schnackenberg, have resulted in shared publications, underscoring a network of ongoing research endeavors in toxicology and related fields.
Metrics
- h-index: 33
- Publications: 100
- Citations: 3,851
Selected Publications
-
Validating and Using Cardiac NAMs for Toxicity Screening and Drug Development (2025)
-
Pexidartinib impairs liver mitochondrial functions causing cell death in primary human hepatocytes at clinically relevant concentrations (2025)
-
Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin (2024)
-
Metabolomics as a Truly Translational Tool for Precision Medicine (2021)
Collaboration Network
Top Collaborators
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Pexidartinib impairs liver mitochondrial functions causing cell death in primary human hepatocytes at clinically relevant concentrations
- Validating and Using Cardiac NAMs for Toxicity Screening and Drug Development
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Pexidartinib impairs liver mitochondrial functions causing cell death in primary human hepatocytes at clinically relevant concentrations
- Validating and Using Cardiac NAMs for Toxicity Screening and Drug Development
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Pexidartinib impairs liver mitochondrial functions causing cell death in primary human hepatocytes at clinically relevant concentrations
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Pexidartinib impairs liver mitochondrial functions causing cell death in primary human hepatocytes at clinically relevant concentrations
- Predicting oncology drug-induced cardiotoxicity with donor-specific iPSC-CMs—a proof-of-concept study with doxorubicin
- Pexidartinib impairs liver mitochondrial functions causing cell death in primary human hepatocytes at clinically relevant concentrations
- Metabolomics as a Truly Translational Tool for Precision Medicine
- Metabolomics as a Truly Translational Tool for Precision Medicine
- Metabolomics as a Truly Translational Tool for Precision Medicine
- Metabolomics as a Truly Translational Tool for Precision Medicine
- Metabolomics as a Truly Translational Tool for Precision Medicine
- Us Fda Public Meeting: Identification of Concepts and Terminology for Multicomponent Biomarkers
- Us Fda Public Meeting: Identification of Concepts and Terminology for Multicomponent Biomarkers
- Us Fda Public Meeting: Identification of Concepts and Terminology for Multicomponent Biomarkers
- Us Fda Public Meeting: Identification of Concepts and Terminology for Multicomponent Biomarkers
- Us Fda Public Meeting: Identification of Concepts and Terminology for Multicomponent Biomarkers
Similar Researchers
Based on overlapping research topics